IGC Pharma Reports 21% Revenue Growth and Improved Net Loss for Quarter Ending June 30, 2025

IGC Pharma, Inc. reported its financial results for the quarter ending June 30, 2025, revealing a revenue of $328,272, a significant increase from $272,000 in the same period last year, marking a growth of approximately 21%. The company’s gross profit for the quarter was $154,163, with a gross margin of 47%, down from 60% in the previous year. The operating loss narrowed to $1,905,000 from $2,396,000, while the net loss attributable to common stockholders was $1,599,000, compared to $2,378,000 in the prior year, reflecting a 33% improvement.

In terms of operational changes, IGC Pharma has focused on optimizing its corporate structure, resulting in a 28% reduction in selling, general, and administrative expenses, which fell to $1,208,000 from $1,670,000. Research and development expenses also decreased slightly to $851,000 from $889,000, primarily due to a one-time non-cash expense recorded in the previous year. The company reported a notable increase in other income, which rose to $306,000 from $18,000, largely attributed to a tax credit received during the quarter.

The company continues to advance its clinical programs, particularly the Phase 2 trial of its lead investigational drug, IGC-AD1, aimed at treating agitation in Alzheimer’s patients. IGC Pharma has expanded its network of clinical trial sites across North America, including locations in Canada and various U.S. states, to enhance patient enrollment and access to diverse populations. The company is also developing an AI-driven diagnostic tool, MINT-AD, to improve early detection of Alzheimer’s disease.

As of June 30, 2025, IGC Pharma's total assets were reported at $7,943,000, a decrease from $8,747,000 at the end of the previous fiscal year. The company’s cash and cash equivalents increased to $454,405, up from $405,000, while working capital decreased by 33% to $428,639. The company has also amended its credit agreement to extend the term of a $12 million facility, which is expected to support ongoing operations and clinical trials.

Looking ahead, IGC Pharma aims to continue its focus on clinical trials and product development while exploring additional funding opportunities, including potential investments in digital assets. The company remains committed to its strategy of developing innovative therapies for Alzheimer’s and related conditions, although it acknowledges the inherent risks and uncertainties associated with clinical trials and market conditions.